

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Yoshimura

Application No. 10/507,385

Filed: September 9, 2004

Confirmation No. 8908

For: USE OF DISCOIDIN DOMAIN
RECEPTOR 1 (DDR1) AND AGENTS
THAT AFFECT THE DDR1/COLLAGEN
PATHWAY

FILED VIA EFS

Examiner: Maria Gomez Leavitt

Art Unit: 1633

Attorney Reference No. 4239-64104-02


FILED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

DECLARATION UNDER 37 C.F.R. §1.132

1. We, Teizo Yoshimura, M.D., Ph.D., and Hidenobu Kamohara, M.D., Ph.D. are the inventors of the above-referenced U.S. Patent Application.
2. Hidenobu Kamohara, Shigeo Yamashiro, Carole Galligan, and Teizo Yoshimura are listed as co-authors of the journal article entitled "Discoidin domain receptor 1 isoform-a (DDR1a) promotes migration of leukocytes in three-dimensional collagen lattices" (*FASEB J.* 2001 Dec; 15(14):2724-26, Epub 2001 Oct 15; hereinafter Kamohara *et al.*), which was published on-line on October 15, 2001.
3. The studies described in Kamohara *et al.* that relate to the claimed invention were the joint contributions of the instant inventors, notwithstanding the inclusion of additional authors on the Kamohara *et al.* reference. The other named authors of Kamohara *et al.*, Shigeo Yamashiro and Carole Galligan, were merely working under our direction and did not contribute to the claimed inventive matter.

5. We hereby declare that all statements made herein are of our own knowledge are true and that all statements made on information and belief are believed to be true. Furthermore, these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of the Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

9/18/2007
Date


Name Teizo Yoshimura, M.D., Ph.D.

Date

Name Hidenobu Kamohara, M.D., Ph.D.